Risk categories and refractory CLL in the era ... - CLL Support

CLL Support

23,137 members39,744 posts

Risk categories and refractory CLL in the era of chemoimmunotherapy

Cllcanada profile image
CllcanadaTop Poster CURE Hero
0 Replies

This full paper has just become available and it is an important topic, unfortunately.

'Refractory CLL has been defined as no response or response lasting < 6 months from last therapy. This subgroup has a very poor outcome, and many trials use this group

as an entry point for early drug development.'

PDF File bloodjournal.hematologylibr...

Written by
Cllcanada profile image
Cllcanada
Top Poster CURE Hero
To view profiles and participate in discussions please or .

Not what you're looking for?

You may also like...

A New Era is Coming up in the Treatment of Chronic Lymphocytic Leukemia

This is an interesting overview from Italy The survival of patients with chronic lymphocytic...

Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory CLL

Overall response rates were 95% (treatment-naïve) and 92% (relapsed/refractory). Thirty-two percent...

High Altitude and CLL: Risk?

I have monitored your support group for a while now and appreciate all the shared information that...

Results of Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory CLL

I think the most surprising thing in this report is that not everyone responds - "The overall...

Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis

Given the interest in my recent response to @[571533] about whether our immune system will get...